No Data
China Prepares 'Extraordinary Efforts' to Counteract Impact of U.S. Tariffs
Express News | Hong Kong Stock Indexes Tank on Monday. Hang Seng Index Down Over 8%. Tencent Drops 8% and Alibaba Plunge Over 11%
Semiconductors rise in adversity, Innovative Drugs make significant strides overseas, and Star companies work together to cope with external shocks.
① The increase in tariffs impacts the global business order, and companies on the Star are responding to challenges with their own innovations, becoming an important force in promoting Technology self-reliance and strength; ② Industry insiders point out that changes in overseas trade policies will force China's high-end manufacturing sector to further enhance its Technology innovation level, Industry Chain resilience, and globalization capabilities, thereby maintaining strategic determination and competitive advantage amidst tariff impacts, and accumulating energy for China to gain initiative in international competition.
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
BeiGene Has Discontinued Its Clinical Development Program For Ociperlimab (BGB-a1217), An Anti-TIGIT Antibody, As A Potential Treatment For Lung Cancer
New executives appointed! Jiangsu Hengrui Pharmaceuticals appoints a new president, aiming to strengthen internationalization?|Quick announcement summary
① Feng Ji, who has worked for AstraZeneca for many years, has officially been appointed as the President and Chief Operating Officer of Jiangsu Hengrui Pharmaceuticals. ② According to industry insiders, the current executive team at Hengrui remains stable, with no significant changes in the roles of other major executives. ③ Industry insiders believe that Jiangsu Hengrui Pharmaceuticals values Feng Ji's experience in multinational pharmaceutical companies.
